We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

77 hedge funds and large institutions have $316M invested in Karyopharm Therapeutics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

958% more call options, than puts

Call options by funds: $1.3M | Put options by funds: $123K

164% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 14

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

26% more capital invested

Capital invested by funds: $251M → $316M (+$64.2M)

5% more funds holding

Funds holding: 73 → 77 (+4)

0.13% more ownership

Funds ownership: 3.93% → 4.06% (+0.13%)

Holders
77
Holders Change
+4
Holders Change %
+5.48%
% of All Funds
1.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
37
Reduced
14
Closed
4
Calls
$1.3M
Puts
$123K
Net Calls
+$1.18M
Net Calls Change
+$751K

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$2.59M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$2.15M
3
Millennium Management
Millennium Management
New York
+$1.45M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.42M
5
IHM
Iguana Healthcare Management
New York
+$955K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.03M
2
SSA
Schonfeld Strategic Advisors
New York
-$716K
3
Citadel Advisors
Citadel Advisors
Florida
-$393K
4
Barclays
Barclays
United Kingdom
-$281K
5
TI
Trexquant Investment
Connecticut
-$202K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$69M +$2.15M +14,978 +4%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$44M -$3.03M -21,133 -7%
PAI
3
Palo Alto Investors
California
$38.4M +$296K +2,067 +0.9%
Franklin Resources
4
Franklin Resources
California
$34.4M +$334K +2,329 +1%
BlackRock
5
BlackRock
New York
$33.4M +$792K +5,528 +3%
Vanguard Group
6
Vanguard Group
Pennsylvania
$19.4M +$1.42M +9,883 +9%
TCM
7
Tekla Capital Management
Massachusetts
$8.31M – – –
State Street
8
State Street
Massachusetts
$6.11M +$425K +2,968 +9%
CS
9
Candriam SCA
Luxembourg
$5.6M +$688K +4,800 +16%
TA
10
Teachers Advisors
New York
$4.74M +$1.43K +10 +0%
Northern Trust
11
Northern Trust
Illinois
$4.57M +$104K +724 +3%
IHM
12
Iguana Healthcare Management
New York
$4.39M +$955K +6,667 +33%
Millennium Management
13
Millennium Management
New York
$4.07M +$1.45M +10,118 +69%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$3.5M -$44.3K -309 -1%
JP Morgan Chase
15
JP Morgan Chase
New York
$3.34M +$2.59M +18,081 +754%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.91M +$45K +314 +2%
SSA
17
Schonfeld Strategic Advisors
New York
$2.75M -$716K -5,000 -23%
BBA
18
Baker Bros. Advisors
New York
$2.38M – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$1.8M +$10.9K +76 +0.7%
Deutsche Bank
20
Deutsche Bank
Germany
$1.78M -$78.3K -547 -5%
MOACM
21
Mutual of America Capital Management
New York
$1.7M – – –
Charles Schwab
22
Charles Schwab
California
$1.54M +$232K +1,621 +21%
NFA
23
Nationwide Fund Advisors
Ohio
$1.16M +$806K +5,624 +396%
OPPM
24
Opus Point Partners Management
New York
$1.1M – – –
TCIM
25
TIAA CREF Investment Management
New York
$996K -$122K -851 -12%
1
2 3 4

KPTI Hedge Fund Activity: Q3 2017 in Review

77 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2017, worth a combined $316M — up 26% from $251M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new KPTI positions and 4 closed out — a net gain of 4 holders — while 37 added to existing stakes and 14 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $2.59M. The largest seller was Fidelity Investments, cutting an estimated $3.03M.

  • 77 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2017, up from 73 in Q2 2017.
  • Funds reported $316M of Karyopharm Therapeutics stock for Q3 2017, up 26% quarter-over-quarter.
  • 8 funds opened new Karyopharm Therapeutics positions in Q3 2017 and 4 closed out, a net change of +4 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2017 was JP Morgan Chase, an estimated $2.59M added.
  • The largest Karyopharm Therapeutics seller in Q3 2017 was Fidelity Investments, an estimated $3.03M sold.

Based on aggregated 13F filings for Q3 2017.